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Abstract
Background
During December 2013, the first locally transmitted chikungunya virus (CHIKV) infections in
the Americas were reported in the Caribbean. Although CHIKV infection is rarely fatal, risk
for severe disease increases with age and medical comorbidities. Herein we describe char-
acteristics of Veterans Health Administration (VHA) patients with CHIKV infection and,
among those with infections diagnosed in Puerto Rico, investigated risk factors for
hospitalization.
Methodology
We queried VHA’s national electronic medical records to identify patients with CHIKV test-
ing during 2014. Demographics, clinical history, laboratory results, and outcomes were
abstracted. We investigated risk factors for hospitalization among patients with laboratory-
confirmed CHIKV infection in Puerto Rico.
Principal Findings
We identified 180 laboratory-confirmed CHIKV infections; 148 (82.2%) were diagnosed in
Puerto Rico, and 32 (17.8%) were diagnosed among returning travelers elsewhere in the
United States. In Puerto Rico, where more patients were hospitalized (55.4% versus
20.0%) and died (4.1% versus 0%), risk for hospitalization increased with age (relative risk
[RR]/each 10-year increase, 1.19; 95% confidence interval [CI], 1.06–1.32) and, adjusted
for age, increased among patients with congestive heart failure (RR, 1.58; 95% CI, 1.25–
1.99), chronic kidney disease (RR, 1.52; 95% CI, 1.19–1.94), diabetes mellitus (RR, 1.39;
95% CI, 1.06–1.84), or chronic lung disease (RR, 1.37; 95% CI, 1.03–1.82).
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Conclusions/Significance
CHIKV infection is an emerging problem among Veterans residing in or visiting areas with
CHIKV transmission. Although overall mortality rates are low, clinicians in affected areas
should be aware that older patients and patients with comorbidities may be at increased risk
for severe disease.
Author Summary
Infection with mosquito-borne chikungunya virus causes fever and severe diffuse joint
pain—an illness known as chikungunya fever, or "that which bends up." Epidemics of chi-
kungunya fever have occurred in Asia, Africa, and Europe. Not until December 2013 were
there reports of chikungunya virus infection occurring in the Americas. Since then, it has
involved most countries in the Western Hemisphere with>1.1 million cases reported by
the end of 2014. Previous data from the Réunion Island outbreak demonstrated that older
patients and patients with certain chronic medical conditions may have a higher risk of
severe disease. The Veterans Health Administration is the largest health care system in the
United States and has facilities in U.S. territories, including Puerto Rico, which has been
heavily affected by this epidemic. Among Veterans in Puerto Rico, we investigated risk fac-
tors for severe disease and described all chikungunya-associated deaths. Risk for hospitali-
zation increased with age, and for patients of the same age, was increased among those
with congestive heart failure, chronic kidney disease, diabetes, or chronic lung disease.
Further work is needed to determine whether prevention strategies targeted to those who
may be at greatest risk for severe disease could help decrease morbidity and mortality
among these populations.
Introduction
Chikungunya virus (CHIKV), an alphavirus most commonly transmitted by Aedes species
mosquitoes, causes chikungunya fever (CHIK), characterized by acute-onset of fever and what
is frequently described as incapacitating polyarthralgia [1, 2]. Since CHIKV was first identified
in Tanzania in 1953 [2], epidemics have occurred in South and Southeast Asia, Africa, and
Europe [1, 3, 4]. Three distinct genotypes have been described, including East/Central/South
African, Asian, and West African [1, 5]. In December 2013, locally transmitted infection in the
Western Hemisphere was first reported; the predominant strain is closely related to the Asian
genotype [6–8]. CHIKV has rapidly disseminated among this largely immunologically naïve
population; the Pan American Health Organization (PAHO) reported>1.1 million suspect
cases, involving the majority of Western Hemisphere countries by the end of 2014 [9]. During
2014, over 31,000 cases (14% laboratory-confirmed) were reported in Puerto Rico [10] and
over 1,500 cases (17% laboratory-confirmed) were reported in the U.S. Virgin Islands [11];
these figures are thought to underestimate disease burden because they do not include patients
who did not present for care nor those who presented, but were not reported or for whom diag-
nostic testing was not completed [12]. During 2014, 2,811 laboratory-confirmed infections in
the United States were reported to the Centers for Disease Control and Prevention (CDC)
through the ArboNET surveillance system; the majority were among returning travelers, except
for 12 persons in Florida with locally transmitted infection [13].
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CHIK is usually self-limited, with the majority of symptoms typically resolving in 7–10 days
[1]; however, patients can have prolonged rheumatologic symptoms [14, 15]. CHIKV infection
can also be associated with severe illness, involving neurologic, cardiovascular, respiratory,
renal, and ocular manifestations [16]. Although overall mortality is low, estimated at 0.3/1,000
population per year on Réunion Island [17], risk for severe disease and death increases with
age and is higher among patients with certain comorbidities [17–19].
The Veterans Health Administration (VHA) has health care facilities throughout the United
States and U.S. territories. Because 45% of all U.S. Veterans and 62% of Veterans in Puerto
Rico are aged65 years [20], and VHA patients have more comorbidities than Veterans who
receive care at non-VHA facilities or non-Veterans [21], VHA patients might be at higher risk
for severe CHIK than those in the general U.S. population exposed to the virus (i.e. returning
travelers and those living in areas with CHIKV transmission). VHA’s Public Health Surveil-
lance and Research Group (PHSR) performs surveillance for emerging infections among VHA
patients. After the CHIK epidemic involved U.S. territories, PHSR began performing CHIK
epidemiologic surveillance in July 2014 of all patients with laboratory-confirmed CHIKV infec-
tion diagnosed at VHA facilities during 2014. Herein, we describe characteristics of these
patients, compare clinical findings with patients who tested negative, investigate risk factors for
hospitalization, and report phylogenetic analysis of CHIKV strains detected.
Methods
We identified patients from all VHA facilities with CHIKV test results for specimens collected
during January 1, 2014–December 31, 2014, utilizing VHA’s Corporate Data Warehouse, a
national data repository from VHA’s VistA electronic medical record system. Because VHA
has no standardized naming convention for laboratory tests and inconsistent application of
universal codes that can be utilized for test identification, we queried this data warehouse for
any test name containing the term "chik." After distributing CHIKV surveillance reports to
VHA facilities beginning in July 2014, PHSR was contacted by VHA facilities that were not
listed in the reports but had diagnosed infections. Consequently, we expanded the query to
search for "chik" in the comments field to capture additional CHIK diagnostic test results asso-
ciated with other test names (e.g., “dengue”, “miscellaneous”, and “reference laboratory”). The
last query was performed on February 26, 2015.
Apart from VHA’s Public Health Reference Laboratory (PHRL), VHA clinical laboratories
do not have CHIK diagnostic testing capability, and thus specimens are sent to non-VHA labo-
ratories for testing. When capacity of non–VHA laboratories in Puerto Rico became over-
whelmed by demand [12], not all specimens submitted for CHIKV testing by Veterans Affairs
Caribbean Healthcare System (VACHS) in Puerto Rico (1 medical center and 8 outpatient clin-
ics) were processed, including some specimens from patients who subsequently died. To further
investigate, we queried the data warehouse for CHIKV testing orders. For patients without
results, medical records were reviewed to determine whether tests remained pending, or if can-
celled, the reason for cancellation. During December 2014, VHA PHSR provided a list of
patients without results to laboratories in Puerto Rico to recover any remaining specimens for
testing by PHRL. PHRL performs internally and externally validated CHIKV reverse transcrip-
tase PCR (RT-PCR) (CDC, CHIKV RT-PCR assay protocol, Fort Collins, Colorado) [22] and
IgM enzyme-linked immunosorbent assay (ELISA) (Abcam, Inc., Anti-Chikungunya Virus IgM
Human ELISA kit, Cambridge, Massachusetts) according to manufacturer’s recommendations.
For patients who had specimens collected for CHIKV testing in Puerto Rico or elsewhere in the
United States and died before the last query was performed, a physician-epidemiologist
reviewed medical records to confirm presenting symptoms were consistent with CHIK (i.e. fever
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and either oligoarthralgia, polyarthralgia, or myalgia) and the patient resided in or had recently
visited an area with CHIKV transmission, and determined whether CHIKV infection might
have contributed to death (i.e., the patient had died before recovery from acute illness and death
was not clearly from unrelated causes). Although PAHO defines a suspect case as a patient with
acute onset of objective fever (>38.5°C or 101.3°F [23, 24];>38.3°C or 101.0°F [9];>38.0°C or
100.4°F [9]) and severe arthralgia, not otherwise explained, who resides in or has visited epi-
demic or endemic areas2 weeks before symptom onset [9, 23, 24], we did not utilize this defi-
nition because the majority of our laboratory-confirmed cases did not meet these criteria.
For all patients with available CHIK diagnostic test results, we abstracted demographics,
clinical history, including symptoms during the acute illness, laboratory results, and outcomes
from medical records. Comorbidities were identified by review of problem lists and provider
notes. A laboratory-positive case was defined as a patient with detectable CHIKV RNA by
RT-PCR or anti-CHIKV IgM antibody. Patients with positive serology, but without travel to
an area with known CHIKV transmission, consistent with a false-positive result, as well as
patients with inadequate testing to rule out CHIKV infection (negative RT-PCR>8 days after
symptom onset and no serology or negative IgM<4 days after symptom onset and no
RT-PCR or convalescent serology) were excluded from statistical analysis [24]. Demographics
and clinical characteristics of patients with laboratory-confirmed infection diagnosed in Puerto
Rico versus elsewhere in the United States were compared, and clinical findings of CHIKV-
positive versus CHIKV-negative patients (all remaining patients with negative CHIKV tests)
were compared by using chi-square test for categorical (Fisher’s exact test when n<5 in any
cell) and t-test for continuous variables.
To determine whether the association between age and hospitalization was modified by
whether CHIK was diagnosed in Puerto Rico versus elsewhere in the United States, analysis was
stratified by patient location. Poisson regression with robust error variance [25, 26] was utilized
to investigate risk factors for hospitalization among patients with laboratory-confirmed infec-
tion in separate age-adjusted models. Potential risk factors investigated included comorbidities,
vital signs on presentation, and laboratory abnormalities at presentation and during clinical
course. Analyses were performed by using SAS 9.2 (SAS Institute, Inc., Cary, North Carolina).
Finally, we sequenced the CHIKV E1 envelope glycoprotein gene from a convenience sample
of patients from Puerto Rico with detectable CHIKV RNA. RNA was extracted from serum by
using Qiagen DSP viral RNAmini kits (Qiagen, Germantown, Maryland) according to manufac-
turer’s instructions. RT-PCR was performed by using Superscript One-Step Platinum Taq HiFi
(Thermo Fisher Scientific, Inc., Waltham, Massachusetts) and primers CV1F and CV1R [27].
Resulting PCR products were purified by using Qiagen PCR purification kits and subjected to
population-based sequencing by using standard dideoxyterminator techniques. Sequences were
assembled, edited, and compared with sequences in GenBank from theWestern Hemisphere
and previous outbreaks using Geneious software (Biomatters, Inc., San Francisco, California).
Ethics Statement
This study was reviewed by CDC for human subjects protection and was deemed to be non-
research. It was also approved by the Stanford University Institutional Review Board and ful-
filled the requirements of regulation OHRP 45 CFR 46.116 (d) for waiver of informed consent.
Patient data was anonymized after data abstraction.
Results
We identified 264 patients with CHIKV results during 2014 (Fig 1). Results for 184 patients
from VACHS in Puerto Rico were available (22.8% of 806 patients from whom specimens were
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collected for CHIK diagnostic testing; testing was not completed for the remainder) (Fig 2 and
S1 Fig). Results for 80 patients were from other U.S. facilities. Twelve patients were excluded; 1
with an apparent false-positive CHIKV IgM/IgG result and 11 with possible false-negative
results because of inadequate testing. The remaining 252 patients, including 180 in Puerto Rico
and 72 elsewhere in the United States, were included in the analysis.
Overall, 180 patients had laboratory-confirmed CHIKV infection (Table 1). Specimens for
CHIKV testing from Puerto Rico were collected a mean of 4.5 d ± 5.4 d from symptom onset.
Specimens from the rest of the United States were collected a mean of 28.7 d ± 40.3 d from
symptom onset (p = 0.003). In Puerto Rico, 148 (82.2%) of 180 patients tested were CHIKV-
positive; 145 (98.0%) were confirmed by RT-PCR and 3 (2.0%) by serology alone. Outside
Puerto Rico, 32 (44.4%) of 72 patients tested were CHIKV-positive; 4 (12.5%) were confirmed
by RT-PCR and 28 (87.5%) by serology alone. Fourteen (19%) of 72 patients tested for CHIKV
infection outside Puerto Rico had no recorded travel to an area with CHIKV transmission
prior to symptom onset, all of whom were CHIKV-negative; none of the patients tested in
Puerto Rico had symptom-onset prior to possible exposure to circulating CHIKV. Patients
with CHIKV infection in Puerto Rico were older (mean, aged 69 versus 55 years; p< .0001)
and had more comorbidities than patients outside Puerto Rico.
Fig 1. Patients with chikungunya virus test results identified—Veterans Health Administration, 2014.One excluded patient with an apparent false-
positive CHIKV IgM/IgG result 4 days after symptom onset had no travel to an area with CHIKV transmission; repeat testing was negative. CHIKV,
chikungunya virus; reverse transcriptase PCR (RT-PCR).
doi:10.1371/journal.pntd.0004630.g001
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Clinical and Laboratory Findings
Patients with CHIKV infection frequently reported oligoarthralgia or polyarthralgia (88.3%),
subjective fever (84.4%), generalized malaise (76.7%), myalgia (69.4%), and rash (44.4%), and
reported these symptoms more often than CHIKV-negative patients (Table 2). Among 165
patients with laboratory-confirmed CHIKV infection who had recorded temperatures during
their acute illness, only 53 (32.1%) demonstrated objective fever (>38.0°C or>100.4°F) [9],
and only 48 (29.1%) had both objective fever and arthralgia. Subjective fever and arthralgia was
reported for 140 (77.8%) of 180 patients and subjective fever or any arthralgia for 174 (96.7%).
Among CHIKV-positive patients, 37.0% of 173 had leukopenia (<4,000 white blood cells
[WBC]/μL) and 71.4% of 171 had lymphopenia (<1,000 lymphocytes/μL); these findings
occurred more frequently compared with CHIKV-negative patients (Table 3). Thrombocyto-
penia (<150,000 platelets/μL) occurred among 80 (46.5%) of 172 patients with CHIKV infec-
tion, with mean nadir platelet count of 104,000/μL. Acute kidney injury (AKI) (0.3 mg/dL or
26.5 μmol/L increase in serum creatinine from last level [28]) was experienced by 33 (21.6%) of
153 patients, 4 (12.1%) of whom had stage III AKI. Hepatic transaminitis (aspartate amino-
transferase>40 U/L or alanine aminotransferase>45 U/L) was experienced by 52 (40.3%) of
129 patients, 16 (30.8%) of whom had transaminases>3 times the upper limit of normal.
Fig 2. Patients with chikungunya virus test results and patients with specimens submitted for chikungunya virus testing without results—
Veterans Affairs Caribbean Healthcare System, 2014 (n = 803). VA PHRL began testing all specimens submitted for chikungunya virus testing from VA
Caribbean Healthcare System on December 11, 2014, including specimens for 13 patients prospectively collected during December and unprocessed
specimens recovered for 74 patients collected during June–November. Reverse transcriptase PCR results are reported by VA PHRL1 day and serology
3 days from specimen receipt.
doi:10.1371/journal.pntd.0004630.g002
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Table 1. Demographics and Clinical Characteristics of Patients with Laboratory-Confirmed Chikungunya Virus Infection—Veterans Health Admin-
istration, 2014 (n = 180).
Puerto Rico n = 148
(82.2%)
United Statesa n = 32
(17.8%)
P
value
Age, mean ± SD, y 68.8 ± 16.2 54.8 ± 16.5 < .0001
Male, no. (%) 142 (96.0) 25 (78.1) .0004
Race/ethnicity, no. (%) < .0001
Hispanic 139 (95.2) 9 (32.1)
White 5 (3.4) 13 (46.4)
Black 1 (0.7) 6 (21.4)
Native Hawaiian or Other Pacific Islander 1 (0.7) 0 (0)
Missing data 2 4
Comorbidities, no. (%)b
Hypertension 118 (79.7) 13 (40.6) < .0001
Hyperlipidemia 101 (68.2) 13 (40.6) .003
Diabetes 62 (41.9) 9 (28.1) .15
Coronary heart disease 32 (21.6) 3 (9.4) .14
Congestive heart failure 13 (8.8) 0 (0) .13
Chronic kidney disease 27 (18.2) 1 (3.1) .03
COPD or pulmonary fibrosis 16 (10.8) 1 (3.1) .31
Asthma 16 (10.8) 5 (15.6) .44
Obstructive sleep apnea 24 (16.2) 4 (12.5) .79
History of malignancy 23 (15.5) 2 (6.3) .26
Dementia 19 (12.8) 0 (0) .03
Immunosuppression 8 (5.4) 0 (0) .35
CHIKV RT-PCR positivity, no. (%) < .0001
Positive 145 (98.6) 4 (40.0)
Negative 2 (1.4) 6 (60.0)
Not performed 1 22
CHIKV IgM positivity, no. (%)c < .0001
Positive 23 (32.9) 29 (93.6)
Negative 47 (67.1) 1 (3.2)
Equivocal 0 (0) 1 (3.2)
Not performed 78 1
Levels of care received, no. (%)b
Primary care provider only 16 (10.8) 10 (33.3) .001
Emergency department 128 (86.5) 20 (66.7) .008
Hospitalized 82 (55.4) 6 (20.0) .0004
Intensive care unit 10 (6.8) 0 (0) .22
Missing data 0 2
Died, no. (%) 6 (4.1) 0 (0) .59
Recent travel among patients who received a diagnosis in the United States (excluding
Puerto Rico), no. (%)d
Puerto Rico 11 (34)
Dominican Republic 8 (25)
Jamaica 4 (13)
Haiti 2 (6)
Dominican Republic and Haiti 2 (6)
U.S. Virgin Islands 1 (3)
Trinidad and Tobago 1 (3)
(Continued)
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Risk Factors Associated with Hospitalization
In Puerto Rico, 82 (55.4%) of 148 patients with laboratory-confirmed CHIKV infection were
hospitalized, including 10 (6.8%) who required intensive care; elsewhere in the United States, 6
(20.0%) of 30 returning travelers with known hospitalization status were hospitalized (p =
.0004). Whereas the hospitalization rate increased with age among patients in Puerto Rico (rel-
ative risk [RR]/ each 10-year increase in age, 1.19; 95% confidence interval [CI], 1.06–1.32), it
did not increase with age among returning travelers. Because only 6 returning travelers were
hospitalized, analysis is only presented for patients in Puerto Rico (Table 4). After adjusting for
age, a significantly higher risk for hospitalization associated with having congestive heart fail-
ure (CHF) (RR, 1.58; 95% CI, 1.25–1.99), chronic kidney disease (CKD) (RR, 1.52; 95% CI,
1.19–1.94), diabetes mellitus (RR, 1.39; 95% CI, 1.06–1.84), or chronic lung disease (RR, 1.37;
95% CI, 1.03–1.82) remained. Adjusted for age, patients had a greater risk for hospitalization if
they were tachycardic (>100 beats/minute; RR, 1.49; 95% CI, 1.12–1.98), had leukocytosis
(>11,000 WBC/μL; RR, 1.65; 95% CI, 1.34–2.03), AKI (RR, 1.64; 95% CI, 1.33–2.04), or hepatic
transaminitis (RR, 1.38; 95% CI, 1.07–1.80) at presentation.
Atypical Features
Two patients with CHIKV infection, confirmed by RT-PCR, developed septic shock without
another identified etiology. One patient, with CHIKV infection confirmed by RT-PCR of
serum, developed meningitis with a CSF profile consistent with a viral etiology, demonstrating
pleocytosis (30 WBC/mm3) with initial predominant monocytosis and elevated protein (88
mg/dL). CSF was not submitted for CHIKV testing and no CSF was recovered for diagnostic
testing by VA PHRL. One patient presented with Guillain-Barré syndrome one month after
CHIK; recent CHIKV infection was confirmed by positive IgM serology. Two patients with
Table 1. (Continued)
Puerto Rico n = 148
(82.2%)
United Statesa n = 32
(17.8%)
P
value
Philippines 1 (3)
Guyana 1 (3)
Ghana 1 (3)
Reason for travel among patients in the United States, no. (%)
Visiting family 15 (52)
Residing in Puerto Rico 7 (24)
Active-duty deployment 3 (10)
Civilians working or volunteering 2 (7)
Vacation 2 (7)
Missing data 3
SD, standard deviation; COPD, chronic obstructive pulmonary disease; CHIKV, chikungunya virus; RT-PCR, reverse transcriptase PCR.
a Excluding Puerto Rico.
b Patients can have >1 comorbidity and receive >1 level of care.
c A second serum specimen was obtained for two patients in the United States who were initially seronegative at 1 and 4 days after symptom onset and
both specimens demonstrated CHIKV IgM seroconversion, at 37 and 21 days after symptom onset respectively; these results are included under positive
CHIKV IgM results. Serologic testing for all but 2 patients in Puerto Rico was performed by the Veterans Health Administration Public Health Reference
Lab.
d One patient was diagnosed in Puerto Rico, but had also travelled to the Dominican Republic.
doi:10.1371/journal.pntd.0004630.t001
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CHIKV infection, confirmed by RT-PCR, presented with diabetic ketoacidosis; one patient
with CHIKV infection, confirmed by RT-PCR, presented with pancreatitis; one patient with
CHIKV infection, confirmed by RT-PCR, presented with colitis, and one patient with CHIKV
infection, confirmed by RT-PCR of serum, experienced monomicrobial nonneutrocytic ascites
(recovered peritoneal fluid collected 20 days after symptom onset was CHIKV IgM and
RT-PCR negative). Seven patients with CHIKV infection (6 confirmed by RT-PCR and 1 by
IgM) experienced pneumonia during their clinical course. Four patients with CHIKV infection,
confirmed by RT-PCR, experienced congestive heart failure exacerbations; three patients with
Table 2. Symptoms and Signs of Patients with Laboratory-Confirmed Chikungunya Virus Infection Compared with Chikungunya Virus-Negative
Patients—Veterans Health Administration, 2014.
System Symptom or Sign CHIKV-positive (n = 180) no. (%) CHIKV-negativea (n = 72) no. (%) P Value
Musculoskeletalb Oligoarthralgia or polyarthralgia 159 (88.3) 45 (62.5) < .0001
Myalgia 125 (69.4) 34 (47.2) .001
Back pain 26 (14.4) 11 (15.3) .87
Neck pain 24 (13.3) 11 (15.3) .69
Bone pain 9 (5.0) 0 (0) .06
Systemic Fever 152 (84.4) 51 (70.8) .01
Generalized malaise or fatigue 138 (76.7) 45 (62.5) .02
Dermatologic Rash 80 (44.4) 16 (22.2) .001
Neurologic Headache 73 (40.6) 27 (37.5) .65
Altered mental status 17 (9.4) 5 (6.9) .53
Dizziness 15 (8.3) 3 (4.2) .29
Gastrointestinal Anorexia 54 (30.0) 22 (30.6) .93
Nausea 48 (26.7) 17 (23.6) .62
Vomiting 27 (15.0) 15 (20.8) .26
Diarrhea 40 (22.2) 10 (13.9) .13
Abdominal pain 24 (13.3) 10 (13.9) .91
Ophthalmologic Conjunctival injection 12 (6.7) 1 (1.4) .12
Pulmonary Cough 34 (18.9) 21 (29.2) .07
Sore throat 16 (8.9) 8 (11.1) .59
Dyspnea 14 (7.8) 7 (9.7) .61
Cardiovascular Chest pain 21 (11.7) 7 (9.7) .66
Edema 13 (7.2) 2 (2.8) .24
Urologic Dysuria 9 (5.0) 2 (2.8) .73
Hematologic Bruising 3 (1.7) 1 (1.4) 1.0
Bleeding 7 (3.9) 4 (5.6) .52
Symptoms and signs during acute illness as recorded in medical records of patients during evaluation for CHIKV infection. Denominator includes all
patients, regardless of whether pertinent negative symptoms or signs were recorded. CHIKV, chikungunya virus.
a Alternative diagnoses were recorded for 34 of 72 CHIKV-negative patients as follows: infectious, 17 (influenza, 1; pneumonia, 4; dengue, 2 [41 (56.9%)
of CHIKV-negative patients had dengue virus test results]; typhoid fever, 1; Q fever, 1; tickborne infection, 1; cellulitis, 1; deep neck space infection, 1;
methicillin-resistant Staphylococcus aureus endocarditis, 1; postinfectious arthritis, 2; aseptic meningitis, 1; colitis, 1); rheumatic, 9 (inflammatory arthritis,
4; suspected Sjögren’s syndrome, 1; suspected spondyloarthopathy, 1; mixed connective tissue disease, 1; osteoarthritis and bursitis, 1; myofascial pain,
1); orthopedic, 1 (prosthetic joint loosening); malignant, 2 (lung cancer and viral syndrome, 1; acute myelogenous leukemia, 1); neurologic, 1
(demyelinating polyneuropathy); adverse drug effect, 1; and fever of unknown origin, 3. Over half (53%) of CHIKV-negative patients had no alternative
diagnosis recorded or received a diagnosis of viral syndrome of undetermined etiology.
b Of 96 patients with CHIKV infection and recorded arthralgia site (59.3% of 162 with any arthralgia), 59 (61%) reported involvement of the knees, 47
(49%) hands or fingers, 36 (38%) ankles, 32 (33%) shoulders, 30 (31%) wrists, 23 (24%) feet, and 19 (20%) elbows.
doi:10.1371/journal.pntd.0004630.t002
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CHIKV infection, confirmed by RT-PCR, presented with syncope; and one patient with
CHIKV infection, confirmed by RT-PCR, experienced a non ST-elevation myocardial infarc-
tion. One patient with CHIKV infection, confirmed by RT-PCR, presented with epididymitis.
Fatalities Associated with Confirmed and Suspected CHIKV Infections in
Puerto Rico
Among the 148 patients with laboratory-confirmed CHIKV infection, 6 (4.1%) died. All had
viremia demonstrated by RT-PCR (Table 5). In addition to these six patients, there were 15
patients who died after presenting with an illness compatible with CHIK that may have con-
tributed to death; specimens for these patients were submitted for CHIKV testing but were not
processed. Although attempts were made to obtain these specimens submitted to non-VHA
laboratories, they were not recovered for testing. These 15 patients are thus considered suspect
cases (data available upon request).
The mean age of patients with laboratory-confirmed CHIKV infection in Puerto Rico who
died was 78 years (range, 66–99 years), compared with 68 years (range, 23–94 years) for those
in Puerto Rico who survived (p = 0.12). All 6 patients who died were afebrile on presentation
(only one had a recorded temperature>100.4°F or>38.0°C during hospitalization); four were
tachycardic on presentation. Of 5 with known medical history, all had multiple comorbidities.
Phylogenetic Analysis
CHIKV E1 envelope glycoprotein gene sequences (GenBank accession numbers:
KU724228-KU724266) for 39 patients in Puerto Rico were closely related (<0.5% nucleotide
Table 3. Abnormal Laboratory Findings for Patients with Laboratory-Confirmed Chikungunya Virus Infection (n = 180), Compared with Chikungu-
nya Virus-Negative Patients (n = 72)—Veterans Health Administration, 2014.
CHIKV-positive CHIKV-Negative P Value
Leukopenia (n = 239), no. (%) 64 (37.0) 15 (22.7) .04
WBC on presentation (n = 78), mean ± SD, cells ×103/μL 4.6 ± 1.4 5.3 ± 3.8
WBC nadir (n = 79), mean ± SD, cells ×103/μL 2.9 ± 0.6 3.0 ± 0.7
Lymphopenia (n = 234), no. (%) 122 (71.4) 24 (38.1) < .0001
ALC on presentation (n = 145), mean ± SD, cells ×103/μL 0.6 ± 0.3 0.7 ± 0.2
ALC nadir (n = 146), mean ± SD cells ×103/μL 0.6 ± 0.2 0.6 ± 0.2
Thrombocytopenia (n = 239), no. (%) 80 (46.5) 28 (41.8) .51
Platelet count on presentation (n = 106), mean ± SD, ×103cells/μL 121 ± 35 121 ± 39
Platelet count nadir (n = 108), mean ± SD, ×103cells/μL 104 ± 31 93 ± 39
Acute kidney injurya (n = 213), no. (%) 33 (21.6) 9 (15.0) .28
Stage I 23 (69.7) 8 (88.9)
Stage II 6 (18.2) 0 (0)
Stage III 4 (12.1) 1 (11.1)
Hepatic transaminitis (n = 184), no. (%) 52 (40.3) 23 (41.8) .85
1–2 × ULN 29 (55.8) 10 (43.5)
2–3 × ULN 7 (13.5) 8 (34.8)
>3 × ULN 16 (30.8) 5 (21.7)
CHIKV, chikungunya virus; WBC, white blood cell count; SD, standard deviation; ALC, absolute lymphocyte count; and ULN, upper limit of normal.
aAcute kidney injury stage I, increase in serum creatinine by 0.3 mg/dL or 26.5 μmol/L from baseline (last creatinine); stage II, 2.0–2.9 × baseline; and
stage III, 3.0 × baseline [28].
doi:10.1371/journal.pntd.0004630.t003
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difference) and nearly identical to strains in GenBank from St. Martin and the British Virgin
Islands (Fig 3) [6, 7].
Discussion
Our study is the first to characterize U.S. Veterans with laboratory-confirmed CHIKV infec-
tion. The majority received a diagnosis in Puerto Rico, although 32 were returning travelers
who received a diagnosis elsewhere in the United States. Although the majority reported sub-
jective fever, only one-third had objective fever, indicating that use of recommended CHIK
case definitions, requiring objective fever, might underestimate disease burden among VHA
patients [24]. Among returning travelers, approximately one-fifth were hospitalized, whereas
in Puerto Rico, where patients were older and had more comorbidities, approximately half of
laboratory-confirmed patients were hospitalized, 6.8% required intensive care, and 4.1% died.
Table 4. Risk Factors Associated with Hospitalization Among Patients with Laboratory-Confirmed Chikungunya Virus Infection—Veterans Affairs
Caribbean Healthcare System, 2014.
Hospitalization
Unadjusted RRa P Value RR, adjusted for agea P Value
Age, per 10-year increase 1.19 (1.06–1.32) .002
Comorbidities
Congestive heart failure 1.78 (1.42–2.23) < .0001 1.58 (1.25–1.99) .0001
Coronary heart disease 1.41 (1.07–1.87) 0.02 1.18 (0.88–1.58) .28
Chronic kidney disease 1.77 (1.40–2.25) < .0001 1.52 (1.19–1.94) .0008
Diabetes mellitus 1.53 (1.15–2.03) .004 1.39 (1.06–1.84) .02
Hypertension 1.35 (0.87–2.09) .18 1.00 (0.63–1.57) .99
Chronic obstructive pulmonary disease or pulmonary fibrosis 1.55 (1.17–2.07) .003 1.37 (1.03–1.82) .03
Asthma 1.15 (0.76–1.73) .52 1.40 (0.92–2.14) .12
Obstructive sleep apnea 1.16 (0.82–1.64) .41 1.40 (1.00–1.95) .05
Dementia 1.52 (1.14–2.02) .004 1.21 (0.90–1.63) .21
History of malignancy 1.32 (0.96–1.81) .09 1.17 (0.85–1.61) .35
Immunosuppression 0.90 (0.44–1.82) .76 0.97 (0.53–1.77) .93
Findings at presentation
Tachycardia 1.35 (1.00–1.82) .049 1.49 (1.12–1.98) .006
Fever (>101.0°F or >38.3°C) 0.93 (0.61–1.42) .74 0.96 (0.62–1.49) .85
Leukocytosis 1.91 (1.63–2.25) < .0001 1.65 (1.34–2.03) < .0001
Leukopenia 1.12 (0.77–1.61) .56 1.14 (0.79–1.65) .49
Lymphopenia 0.83 (0.61–1.12) .22 0.80 (0.60–1.08) .14
Thrombocytopenia 1.39 (1.05–1.85) .02 1.27 (0.96–1.68) .09
Acute kidney injury 1.80 (1.48–2.19) < .0001 1.64 (1.33–2.04) < .0001
Hepatic transaminitis 1.44 (1.10–1.87) .007 1.38 (1.07–1.80) .01
Findings during clinical course
Thrombocytopenia 1.66 (1.22–2.27) .001 1.55 (1.15–2.10) .004
Acute kidney injury 1.88 (1.52–2.32) < .0001 1.75 (1.40–2.19) < .0001
Hepatic transaminitis 1.50 (1.15–1.97) .003 1.44 (1.10–1.88) .008
Missing data, findings on presentation: tachycardia (n = 2), fever (n = 2), leukocytosis (n = 4), leukopenia (n = 4), lymphopenia (n = 4), thrombocytopenia
(n = 5), acute kidney injury (n = 14), hepatic transaminitis (n = 39); findings during clinical course: thrombocytopenia (n = 3), acute kidney injury (n = 13),
and hepatic transaminitis (n = 36). RR, relative risk.
a Reference groups for all categorical variables were patients with laboratory-confirmed CHIKV infection without the condition indicated.
doi:10.1371/journal.pntd.0004630.t004
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Fig 3. Phylogenetic tree comparing sequences of chikungunya virus strains from Puerto Rico with strains from other regions. Sequences (700 bp)
from the E1 envelope glycoprotein gene were aligned and compared in a neighbor-joining tree with a Jukes-Cantor model and 1000 bootstrapping replicates.
The resulting tree, with GenBank accession numbers, was displayed by using FigTree v1.2 (http://tree.bio.ed.ac.uk/software/figtree/). The scale bar indicates
the distance corresponding with 0.01 nucleotide substitutions per site.
doi:10.1371/journal.pntd.0004630.g003
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The fatality rate was higher among VHA patients compared with a preliminary report from
Puerto Rico in December 2014 that described only 4 deaths identified by passive surveillance
on the island [12]. Although we performed population sequencing of only a portion of the E1
envelope glycoprotein gene, we did not find substantial difference among sequences from
Puerto Rico compared with other strains circulating in the Western Hemisphere [6, 7]. As in
previous studies [18, 19], we report that age was associated with increased risk for hospitaliza-
tion. After adjusting for age, CHF (but not coronary heart disease), CKD, diabetes, and chronic
lung disease were associated with increased risk for hospitalization. While we cannot be certain
of the individual physicians' criteria for hospitalization in many cases, we do know that patients
were more likely to be hospitalized if they had unstable vital signs (e.g. tachycardia) or had
abnormal laboratory results (e.g. leukocytosis, acute kidney injury, or hepatic transaminitis) at
presentation.
Although literature review demonstrates low overall mortality, among persons with CHIKV
infection presenting for care, the case fatality rate is not insignificant. During the CHIKV out-
break on Réunion Island (East/Central/South African genotype) [29], among 157 patients with
laboratory-confirmed infection who presented to a medical center, 61.8% were hospitalized
and 3.2% died [18]. Although patients in that study were>10 years younger and fewer had
comorbidities, hospitalization and case fatality rates were similar to VACHS. They reported
that diabetes and ischemic heart disease, unadjusted for age, was associated with increased
odds of hospitalization [18]; only 11 patients in that study had CKD. Economopoulou et al.
reported that among a subset of hospitalized patients with CHIK, cardiac disease, respiratory
disease, as well as hypertension were associated with increased risk for severe disease [19].
Because our study included patients with laboratory-confirmed CHIKV infection, we can-
not assess the overall burden of CHIKV infection among Veterans, only those who presented
to VHA facilities and had appropriate diagnostic testing completed. During 2014, investigation
of households surrounding laboratory-positive cases demonstrated that 28% of participants
were laboratory-positive for current or recent CHIKV infection, and only 63% of symptomatic
persons had sought care [12]. Although our query was robust, any patient with results not
entered into the laboratory component of the electronic medical record (e.g., scanned or
recorded in a progress note) would not have been captured. Sample size limited analysis of
returning travelers, and in Puerto Rico, prevented inclusion of>1 comorbidity in age-adjusted
models or assessment of risk factors for intensive care or death among patients with labora-
tory-confirmed infection. This study identified the lack of testing availability for VACHS, as
well as deficiencies in CHIKV diagnostic testing across VHA. We identified 11 patients (4 in
Puerto Rico and 7 elsewhere in the United States) with inadequate testing to diagnose CHIKV
infection, which may have contributed to underdiagnosis of CHIKV-infection. In Puerto Rico
this was because of underuse of serology for patients who presented>8 days after symptom
onset. Outside Puerto Rico this was because of underuse of CHIKV RT-PCR or convalescent
serology for patients who presented during the first week of symptom onset. Among returning
travelers, many of whom presented for care in the U.S. during the convalescent period, when
diagnosis is dependent upon serology, some diagnoses could have been missed as CHIKV IgM
typically declines after several weeks to months [1]. Only 4 of the returning travelers had
CHIKV IgM performed without simultaneous CHIKV IgG, and no patients had a negative
CHIKV IgM and positive CHIKV IgG, however, suggesting that few cases may have been
missed for this reason. Outside Puerto Rico, only 44% of patients tested for CHIKV had labora-
tory-confirmed infection; this not only reflects the lower prevalence of CHIKV infection out-
side Puerto Rico, but also improper testing of patients without symptom-onset after travel to
an area with CHIKV transmission. Our surveillance activities determined that CHIKV testing
availability for VACHS was lacking and resulted in VHA PHRL offering CHIKV (and dengue
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virus) testing. Further education of VHA providers regarding CHIKV infection, correct diag-
nostic testing (RT-PCR versus serology) on the basis of time from symptom onset, and avail-
able testing through VHA is needed.
Lessons learned from Puerto Rico are important for areas in the Western Hemisphere with
ongoing CHIKV transmission as well as countries, including the United States, with similarly
immunologically naïve populations and Aedes aegypti or Aedes albopictus vectors [6]. For clini-
cal management, newly required CHIK public health reporting, and surveillance, having ade-
quate laboratory testing capacity for timely results is helpful. Although testing all symptomatic
persons might be infeasible, sufficient capacity to test those with severe (e.g. hospitalized
patients) or atypical illness is needed. Clinicians practicing in areas with CHIKV transmission
should be aware that CHIKV infection among elderly patients and patients with comorbidities,
including CHF, CKD, diabetes, and chronic lung disease may be associated with more severe
disease. To determine whether the risk of atypical complications is greater for CHIKV infection
compared with other viral infections, a larger cohort of patients presenting with a viral syn-
drome would need to be studied. Further work to examine risk factors for intensive care and
death among a larger sample of patients with laboratory-confirmed infection is needed to pro-
vide closer monitoring for those at greatest risk and to investigate the effect of prevention strat-
egies [30] targeted to populations at greatest risk should they acquire CHIKV infection.
Supporting Information
S1 Fig. Results received for patients who had specimens collected for chikungunya virus
testing—Veterans Affairs Caribbean Healthcare System, 2014.Of 806 patients who had
specimens collected for chikungunya virus testing, 184 (22.8%) were tested. Of 716 patients
who had specimens submitted to non-Veterans Health Administration laboratories in Puerto
Rico for chikungunya virus testing, results were received for 97 (13.5%). Reasons provided for
rejected specimens (n = 32) included incomplete information (symptom onset date or date of
birth not specified), 29; no case investigation form, 1; discrepancy between specimen and form,
1; and unknown, 1. CHIKV, chikungunya virus; VHA, Veterans Health Administration; PHRL
Public Health Reference Laboratory; and PR DoH, Puerto Rico Department of Health.
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